Tuesday, December 12, 2006

Bagolie & Friedman Lecture to Lawyers on Workers' Compensation Practice


New Jersey - December 2006 - Workers' Compensation Trial Lawyers Ricky Bagolie and Alan Friedman were invited to speak to a group of lawyers interested in advanced workers' comp trial tips. The unique program took place on December 2 at Pines Manor in Edison and was sponsored by the Association of Trial Lawyers of America - New Jersey (ATLA-NJ). It featured a panel of some of the most respected workers’ compensation attorneys in the state.

The program was packed with practice pointers that have proven successful in matters ranging from Using Epidemiology to Cross Examining Defense Experts, Post Settlement Enforcement Motions, Navigating the Latest Lien Issues and the Ethical Considerations in Dealing with Problem Clients. "Attendees took home new ideas that they could immediately apply to their current and future cases", said Bagolie.

Ricky Bagolie and Alan Friedman have lectured to attorneys locally, nationally as well as internationally and are the founding members of Bagolie Friedman Injury Lawyers, of Jersey City & Clifton, NJ and affiliate offices in Hollywood, Florida and Brisbane, Australia may be reached toll free at 1-866-333-3529, via e-mail at info@bagoliefriedman.com

Wednesday, December 06, 2006

OSHA Report Of Asbestos in Brake Pads Gets Congressional Scrutiny

Andrew Schneider of the Baltimore Sun reported that OSHA had threatened to suspend an employee for refusing to withdraw an OSHA bulletin describing the hazards of asbestos in brake pads, Asbestos-Automotive Brake and Clutch Repair Work. The article also suggested that former Assistant Secretary of Labor for OSHA, John Henshaw, had inappropriately influenced the agency to rescind the bulletin.

Congressman George Miller (D-CA), soon-to-be chairman of the House Committee on Education and the Workforce sent a letter to Secretary of Labor Elaine Chao saying that he was "alarmed to learn that OSHA was withdrawing and replacing" the bulletin.

Equally disturbing, according to Miller, is the news that DOL proposed to suspend the OSHA employee who drafted the original safety bulletin."

Miller requested all documents relating to communications between OSHA and the Office of Management and Budget, documents relating to Henshaws communications with the Department relating to the bulletin and all documents relating to the development of the bulletin.

Thank goodness that, finally, we have someone in Congress that will be looking out for worker safety.

Saturday, October 28, 2006

Will New Jersey Workers' Comp Benefits Be Extended to Same Sex Couples

"Disparate treatment of committed same-sex couples, moreover, directly
disadvantages their children. We fail to see any legitimate
governmental purpose in disallowing the child of a deceased same-sex
parent survivor benefits under the Workers' Compensation Act or
Criminal Injuries Compensation Act when children of married parents
would be entitled to such benefits."
Mark Lewis and Dennis Winslow, et al. v. Gwendolyn L. Harris, etc., et al. (A-68-05) Complete Decision: http://www.judiciary.state.nj.us/opinions/supreme/a-68-05.pdf

Bagolie Friedman Injury Lawyers are looking to investigate workers' compensation claims involving same sex couples and may be reached toll free at 1-866-333-3529.

Bankruptcy Court Approves Owens Corning's Plan of Reorganization

Toledo, Ohio – September 26, 2006 – Owens Corning (OWENQ.OB) today announced
that Judge Judith Fitzgerald of the United States Bankruptcy Court for the District of Delaware approved the company’s Plan of Reorganization. The Bankruptcy Court’s
approval of the plan paves the way for Owens Corning to emerge from bankruptcy by
the end of October 2006.

“The court’s approval of Owens Corning’s Plan of Reorganization is a significant
accomplishment for our company,” said Dave Brown, president and chief executive
officer. “As a direct result of the hard work of our employees and the continued support of our customers, suppliers and business partners, Owens Corning has the strong business performance and financial resources necessary to make this plan possible. We are pleased to have court approval on a plan that deals fairly and equitably with all our creditors and permanently resolves our asbestos liability.

“Throughout the Chapter 11 process, Owens Corning has remained committed to fairly
compensating individuals who were made sick by exposure to asbestos-containing
products that we produced until 1972,” said Mr. Brown. “This plan allows us to achieve that objective through the funding of a Trust that will allow those affected by asbestos to be compensated in the near future.”

Owens Corning’s creditors and shareholders overwhelmingly supported the plan,
including the asbestos, bondholder, and trade creditor classes, and bank debt holders. Before Owens Corning can emerge from bankruptcy, the plan must also be approved by Judge John P. Fullam of the United States District Court for the Eastern District of Pennsylvania. Following district court approval of the plan, Owens Corning must complete certain administrative steps before it can emerge from Chapter 11.

“We will emerge as a strong company,” said Mr. Brown. “Since 2002, we have
strengthened our financial performance, including increased sales, improved income
from operations and reduced SG&A. These financial achievements are reflected in the
preliminary investment-grade credit ratings that we received from both Standard &
Poor’s and Moody’s, an unprecedented accomplishment for a company emerging from a
bankruptcy restructuring.”

The agreement assumes a total distributable value of $8.627 billion, consisting of the total enterprise value of $5.858 billion, assumed excess cash of $1.432 billion, and Fibreboard trust and asbestos trust assets of $1.491 billion, less existing debt of $55 million and $99 million in assumed value of new shares reserved for employee incentive programs. The full Plan of Reorganization and related Disclosure Statement are available at http://www.ocplan.com.

Owens Corning’s exit financing will come from a combination of new equity, new debt
financing and existing debt at non-debtor Owens Corning entities. The company will
begin distributions to creditors upon the effective date of its emergence from Chapter 11.

About Owens Corning

Owens Corning is a world leader in building materials systems and composite solutions. A Fortune 500 company for more than 50 years, Owens Corning people redefine what is possible each day to deliver high-quality products and services ranging from insulation, roofing, siding and stone, to glass composite materials used in transportation, electronic, telecommunications and other high-performance applications. Since the company’s founding in 1938, Owens Corning has become a market-leading innovator of glass fiber technology with sales of $6.3 billion in 2005 and 20,000 employees in 26 countries. Additional information is available at http://www.owenscorning.com.

On October 5, 2000, Owens Corning and 17 United States subsidiaries filed voluntary petitions for relief under Chapter 11 of the U. S. Bankruptcy Code in the U. S. Bankruptcy Court for the District of Delaware. The Debtors are currently
operating their businesses as debtors-in-possession in accordance with provisions of the Bankruptcy Code. The Chapter 11 cases of the Debtors are being jointly administered under Case No. 00-3837 (JKF). The Chapter 11 cases do not
include other U. S. subsidiaries of Owens Corning or any of its foreign subsidiaries. The Debtors filed for relief under Chapter 11 to address the growing demands on Owens Corning's cash flow resulting from the substantial costs of
asbestos personal injury liability.
...................

Reference
Owens Illinois Bankruptcy Site:
http://www.occlaims.com/

Thursday, October 26, 2006

Excessive Cancer Deaths Found Among IBM Manufacturing Employees

Excessive Cancer Deaths Found Among IBM Manufacturing Employees
Alliance@IBM CWA Local 1701 Calls on IBM to Take Action
Oct 23, 2006 | PRNewswire
A study by Dr. Richard Clapp an epidemiologist at Boston University School of Public health, and published in Environmental Health Journal has raised alarms with IBM employees and retirees. The study, called "Mortality among US employees of a large computer company: 1969-2001," specifically details cancers and mortality rates among IBM employees.

The study confirmed that overall and cancer related mortality is considerably higher among workers engaged in manufacturing computers and component parts when compared with the general population. While this was generally known, this study includes data from the largest database so far IBM's own "Corporate Mortality File." The data comes from 31,941 records about the deaths of people who had worked at IBM's plants for at least 5 years. The study is on the Alliance web site at http://www.allianceibm.org

Earl Mongeon, Alliance@IBM Vice President and a manufacturing worker at the IBM Burlington Vermont site, said: "This study confirms to those of us working in IBM manufacturing processes that the rumors and talk about high levels of cancers and other health problems from working with toxic substances wasn't just idle shop floor talk."


The Alliance@IBM, the advocate group for IBM employees, is calling on IBM and local, state and federal officials to take the following actions in response to this study:

Health surveillance of all who worked at IBM by the company and appropriate Health agencies.
Increase the use of non-toxic substances in all processes and reduce the use of harmful substances.
Employee exposure levels of toxic substances within IBM facilities be reduced significantly.
States and municipalities with computer manufacturing plants to compile cancer maps of areas around the facilities and areas where employees are likely to reside. Results to be made public.
The setting up of a fund to help alleviate the medical costs of affected IBM employees and their families

If you or a loved one developed a cancer that may be related to the job, contact Bagolie Friedman Injury Lawyers now for a confidetial and free consultation.

Wednesday, October 18, 2006

Idaho Teen Sues J&J, Ortho McNeil Over Ortho Evra Birth-Control Patch

Idaho Teen Sues J&J, Ortho McNeil Over Ortho Evra Birth-Control Patch

A new lawsuit was filed in federal court regarding the safety of the popular but controversial birth-control patch Ortho Evra. In the suit, Idaho’s Katy McKellips Braman, who was 17 when she was first prescribed the patch in 2004, claims that Johnson & Johnson and drug company Ortho McNeil failed to sufficiently test the patch before putting it on the market and that they knowingly misled consumers about the risks of the patch when compared to other birth-control alternatives. Braman’s suit is one of hundreds that have been filed throughout the United States.

Braman alleges that she developed deep vein thrombosis, a serious and potentially fatal blood-clot condition, in her left leg because of her use of Ortho Evra. She had been using the drug for little more than a month when she noticed pronounced swelling in the leg, which gradually worsened over the course of days. The condition required hospital treatment and has forced her to take anti-clotting medications on a daily basis. She is suing the companies for damages and all future medical costs related to the condition.


Only last month, the Food and Drug Administration added a warning to the Ortha Evra label, notifying consumers of the increased risks of clotting in legs and lungs for the patch as opposed to the pill. The patch works by releasing estrogen and progestin into the blood. Since it is applied only on a weekly basis, it contains significantly more hormones than more traditional forms of birth control–making the risk of side effects more severe. Last year, there were nearly 9.5 million prescriptions written for Ortho Evra.

In April of this year, the New York Post reported that “women who suffered life-threatening blood clots and strokes on the Ortho Evra birth-control patch have been receiving cash settlements from the manufacturer.” In September, the Post said that “FDA records, obtained by The Post under the Freedom of Information law, show that 17 patch users, ages 17 to 30, suffered fatal heart attacks, blood clots, and possible strokes since August 2002” and added that “scores of other women using the Ortho Evra patch have suffered complications, including 21 ‘life-threatening’ cases of blood clots and other ailments, according to Food and Drug Administration reports obtained by The Post.”

Johnson & Johnson reported in an SEC filing earlier this year that roughly 500 women had filed suit against them over the patch. Earlier today, the company announced profits of more than $2.7 billion in the third quarter alone, on revenues of $13.3 billion. However, hormonal contraceptive sales declined by 4 percent, largely because of the safety issues related to the patch.

Contact Bagolie Friedman Injury Lawyers now for a confidential and free consultation now.

Sunday, October 08, 2006

Jury awards a former railroad employee $1.8 million after he claimed exposure to cleaning solvent at work in Louisville and Corbin caused permane

By James Bruggers
jbruggers@courier-journal.com
According to The Courier-Journal


A Jefferson Circuit Court jury has awarded a former railroad employee $1.8 million after he claimed exposure to cleaning solvent at work in Louisville and Corbin caused permanent brain damage.

Terry L. Williams, 59, of Corbin, had targeted his former employer, CSX Transportation, in the lawsuit. He declined to be interviewed.



CSX spokesman Gary Sease declined to comment. Sease has previously said that the company does not believe solvents sickened workers at CSX or companies that CSX acquired, such as the Louisville & Nashville Railroad.

But the 9-3 verdict in the two-week trial is the latest in a string of litigation in several states involving hundreds of railroad workers.

The Louisville jury awarded Williams $500,000 for medical expenses, $500,000 for loss of income, $500,000 for past mental and physical pain and suffering and $500,000 for future mental and physical pain and suffering, according to court documents filed Tuesday.

Because the jury attributed 10 percent of the negligence to Williams, CSX will be obligated to pay 90 percent of the award, or $1.8 million.

Williams worked for the railroad 34 years, leaving in 2000 after having been diagnosed with toxic encephalopathy. Williams' career as a machinist working on locomotives started at the L&N's old South Louisville shops and ended at a maintenance facility in Corbin.

In 2001 The Courier-Journal found that more than 600 U.S. railroad employees had been diagnosed with brain damage after working years with solvents with little or no protection.

CSX had, as of 2001, paid $35 million in settlements or awards to 466 current or former employees who filed claims under the federal compensation law for railroad employees. Jury verdicts have gone both ways, with railroad companies claiming other factors may have caused illnesses.

Railroads largely phased out use of the chemicals in question by the early 1990s.

Earlier this year, researchers in West Virginia documented that solvents used by railroad workers shrank an area that helps the two sides of the brain communicate.

Contact Bagolie Friedman Injury Lawyers to discuss your potential railroad claim.

Wednesday, September 06, 2006

Workers Comp & Injury Law Blog: Lawsuit Accuses Security Firm of Failing to Pay Overtime

Workers Comp & Injury Law Blog: Lawsuit Accuses Security Firm of Failing to Pay Overtime

Lawsuit Accuses Security Firm of Failing to Pay Overtime

According to Business Wire, Inter-Con, a global security firm, faces a lawsuit for failing to pay current and former employees for required pre-shift overtime work and violating state and federal laws. The class consists of about 2,000 security guards in CA and there is possibility of more throughout other states. The lawsuit seeks an injunction that would require Inter-Con to pay overtime wages and compensation for all current and former employees who were denied overtime pay in CA.

If you feel that you were cheated out of overtime, contact Bagolie Friedman Injury Lawyers now for a confidential and free consultation.

BAGOLIE FRIEDMAN
INJURY LAWYERS

The Five Corners Building
660 Newark Avenue
Jersey City, New Jersey 07306

201-656-8500 phone
201-656-4702 fax

e-mail: ricky@bagoliefriedman.com
e-mail: rickybags@aol.com

Visit our website now at: www.bagoliefriedman.com
Blog with us at: www.bagoliefriedman.com or www.jerseycity.injuryboard.com

Affiliate Offices: Clifton, New Jersey - Hollywood, Florida - Brisbane, Australia

Wednesday, August 30, 2006

Federal Prosecutors Will Appeal Pending Asbestos Case Rulings

Federal Prosecutors Will Appeal Pending Asbestos Case Rulings

A case against W.R. Grace and Co. over an asbestos conspiracy will be appealed by federal prosecutors who disagree with recent court rulings. The prosecutors accuse the company of violating the Clean Air Act and knowingly poisoning former workers and residents. Three rulings however, have undermined their case by dismissing one count of conspiracy and barring the use of "critical evidence" of asbestos samples and scientific research. The Washington Post, Boston Globe 08/25/2006

Beware of Asbestos in Automotive Brake & Clutch Repair Work

Asbestos-Automotive Brake and Clutch Repair Work
SHIB 07-26-2006
"OSHA is issuing this Safety and Health Information Bulletin to inform employees and employers in the automotive brake repair industry of the precautions that must be taken when working with automotive brakes and clutches containing asbestos. In the case of do-it-yourselfers *, OSHA does not have jurisdiction, and OSHA does not require theses practices to be followed. To reduce the potential exposure to asbestos, EPA strongly recommends that all automotive brake and clutch repair work be done by professional auto mechanics. "

If you or a loved one suffers from an asbestos related injury, contact Bagolie Friedman Injury Lawyers for a confidential and free consultation.

Saturday, August 26, 2006

Ortho Evra Lawsuit Filed

A law suit has been filed against Ortho-McNeil Pharmaceutical, Inc., a division of Johnson and Johnson Inc. (NYSE:JNJ), on behalf of a 34 year-old woman. The woman was diagnosed with a severe pulmonary embolism after using the Ortho Evra birth control patch less than two years. The suit was filed in the United States District Court for the District of New Jersey earlier this month.

Saturday, August 12, 2006

Workers Comp & Injury Law Blog: Nationwide Recall of Duragesic Patches Expanded

Workers Comp & Injury Law Blog: Nationwide Recall of Duragesic Patches Expanded

Charite Artificial Disc Recipients Take Legal Steps

Artificial Disc Recipients Take Legal Steps
There are success stories, but more than two dozen patients claim the device is too risky
Aug 4, 2006 | Rong-Gong Lin II | Los Angeles Times
Since the moment a decade ago when Dane Titsworth picked up a box and a disc in his spine burst, he has been in ever-worsening pain.

So it was with great hope that the Bakersfield building maintenance manager agreed last year to a new procedure. It meant replacing the deteriorating disc in his lower back with a Charite-brand artificial one the first artificial replacement disc approved in the U.S.

"The artificial disc was going to restore my full motion and relieve all my pain," he recalled being told by his doctor. "I would be like a new person."

But after the surgery, he said, the pain became excruciating, virtually immobilizing him. He could no longer work, garden, play catch or ride his motorcycle. After about 10 months on sick leave, he lost his job.

"It failed," said Titsworth, 45, a married father of a 13-year-old son and 2-year-old daughter. "It's pretty much stopped my life." And now he is suing the disc's maker, DePuy Spine Inc., a Raynham, Mass.-based subsidiary of Johnson & Johnson.

Used in Europe since the 1980s and approved by the Food and Drug Administration in 2004, the Charite disc is marketed as an alternative to spinal fusion and is part of the growing and sometimes controversial use of spinal surgery.

The disc's maker says the product is safe and has helped thousands of patients. But DePuy had no comment on Titsworth's case or 27 similar lawsuits filed since January. Five involve California plaintiffs.

The suits allege that the disc is "unreasonably dangerous."

"They've designed a defective product that does not work as intended or as advertised, and in fact causes some horrific side effects," said Titsworth's lawyer.

DePuy spokeswoman Debbie Williams says the product garnered high satisfaction rates among patients and surgeons in a two-year, industry-funded study that was filed with the FDA before its approval.

"As with all surgical procedures, there is a potential for adverse events or complications," Williams said in an e-mail. Still, "the clinical evidence shows the Charite artificial disc is an effective treatment and an option for appropriate patients."

She said that the product "preserves some motion" and "has demonstrated a shorter recovery time compared to fusion." Spinal fusion, the leading surgical treatment for damaged discs, involves placing bone grafts around two or more of the vertebrae during surgery. The body then heals the grafts over several months, which "welds" the vertebrae into a rigid section.

Dr. John Regan, a Beverly Hills surgeon who performs surgery using the artificial disc, said fusion might add stress on adjacent, healthier discs, increasing the risk of future damage.

In contrast, an artificial replacement disc is designed to keep the damaged area flexible, said Regan, who receives some royalties from DePuy unrelated to surgeries he has performed.

Some patients say the Charite disc has given them a new chance for an active lifestyle they thought had been lost forever.

Ron Osborn, 57, of Saugus, said he was surprised at how well his Charite disc has performed. The natural disc it replaced had deteriorated so much that the bones on his spine were crushing a major nerve, leaving him unable to walk for weeks at a time.

"Now I'm back," said Osborn, a sales manager for a golf company. "I've got 100% restoration. I have a back of a 20-year-old."

Similarly, Rick Zayed, 38, an aerospace mechanical engineer from Hermosa Beach, went from struggling to lift a laundry basket to swimming, running and mountain biking.

"So far, everything they said it would do, it's been doing," Zayed said.

But Dr. Allyson Fried-Cain, a former foot-and-ankle surgeon who has sued the manufacturer, said that she suffered such an increase in pain after a Charite disc implantation that she lost her practice and had to sell her Marina del Rey home.

"I couldn't do surgery anymore. I couldn't bend over," said Fried-Cain, 52, a former marathon runner whose back injury resulted from a car accident.

"This implant has destroyed my life," she said.

The Charite disc is advertised on its website with the trademarked slogan "natural motion is back," along with a photo of a family walking through a field.

The suits come as spinal surgery is becoming a very lucrative business, with at least $3.2 billion spent last year in the U.S. on spinal fusion.

Millions of Americans who suffer from persistent lower back pain are looking for relief, and employers lose billions of dollars every year from lost work time due to back pain.

Other medical device companies, including West Chester, Pa.-based Synthes Inc. and Minneapolis-based Medtronic Inc., are developing disc replacements.

"It's an enormous commercial opportunity," said Phil Nabone, a medical technology analyst at RBC Capital Markets.

But since its launch, the Charite disc has been controversial.

Although two national insurance carriers and 60 regional providers cover the device, a medical advisory panel for the Blue Cross Blue Shield Assn. said in an evidence-based review last year that there was "no immediately evident advantage" to using the artificial disc.

And this year, the U.S. Centers for Medicare and Medicaid Services questioned the disc's overall effectiveness.

The original two-year trial sent to the FDA showed only that the disc was no worse than a specific type of spinal fusion surgery, the agency said in a 45-page report released in May.

The study is sometimes criticized because it compared the disc with a spinal fusion technique that has fallen out of favor among surgeons.

The trial submitted to the FDA found that 57% of Charite patients achieved "overall clinical success," compared with 47% in the spinal fusion procedure. More than 3 in 5 Charite disc patients who were considered successes continued taking narcotic pain killers two years after the surgery; while 4 in 5 did so in the control group.

But a higher percentage of Charite disc patients suffered severe or life-threatening events than the spinal fusion group: 15% compared with 9%, according to an FDA clinical review.

As a result, the agency ruled that Medicare would bar coverage of the device for anyone older than 60. Local Medicare contractors were allowed to make the decision for anyone younger.

"This composite outcome is unconvincing as a demonstration of health benefit," the Medicare report said.

Some doctors are equally skeptical.

Dr. Sohail Mirza, a University of Washington medical professor, took issue with Charite disc's marketing slogan of "natural motion is back." It "implies that the artificial disc creates a normal spine; it does not," he wrote in the journal Spine last year.

"Contrary to optimistic marketing, the data … argue for caution by patients and surgeons. Hope for a cure of back pain and a marketing bonanza must be held in check," he wrote.

Dr. Charles Rosen, associate clinical professor of spine surgery at UC Irvine, said he has seen 10 patients since late last year, including Titsworth, complaining of worsening pain after they received the Charite disc.

Rosen said he believes the disc is unsafe and should never have been approved by the FDA. After the surgery, some patients suffered fracturing and an abnormal pulling apart of the joints of the spine, he said. Rosen said the two-year study was too short for a disc that will remain in the spine for many years; the average age of a disc recipient is 40.

"There is no solid evidence that this will last for more than five or 10 years and they will not need to have another operation," Rosen said.

Regan, who helped conduct the clinical trial for the Charite disc, said he is convinced the disc is good technology.

"When you focus on the failures, everyone's thinking, 'What's wrong with this?' " Regan said. "Then it spoils it for the many, many patients who are doing great."

If you or a loved one suffer from problems due to a Charite Artificial Disc, contact Bagolie Friedman Injury Lawyers for a confidential and free consultation.

Injured by the Duragesic Fentanyl Patch?

Injured by the Duragesic Patch?
On July 15, 2005 the FDA issued a Public Health Advisory concerning the use of Duragesic Patches (Fentanyl transdermal) in response to reports of deaths in patients using the patch. The FDA is conducting an investigation into the deaths associated with these patches.

The Agency has been examining the circumstances of product use to determine if the reported adverse events may be related to inappropriate use of the patch or factors related to the quality of the product. It is possible that some patients and their health care providers may not be completely aware of the dangers of these potent narcotic drug products and the important recommendations regarding their safe use.

There has been an expanded recall of Duragesic Patches due to possible leaks. Janssen Pharmaceutica, the manufacturer of the Duragesic Patch notified healthcare professionals of an expanded recall of the Duragesic 75 mcg/h, in February 2004. Four additional lots have been subject to the present expanded recall. Some patches from the recalled lots may leak medication due to improper sealing of one of their edges.

If the medication leaks out of the patch, exposure to the medication can result in inadvertent ingestion or increased transdermal absorption of the active opiate component fentanyl, leading to potentially life-threatening complications. In addition, leakage of the medication could lead to inadequate dosing, resulting in treatment failure and/or opiate withdrawal.

The Duragesic Patch is indicated for the management of severe, chronic pain (such as cancer pain) that cannot be managed with less powerful drugs such as acetaminophen-opioid combinations and nonsteroidal analgesics.

Moreover, only patients who are already on and tolerant to opioid therapy, and require continuous opioid administration should use the patch. Approved by the U.S. Food and Drug Administration (FDA) in 1990, the Duragesic patch releases fentanyl, a strong opioid, through the skin at a fixed rate for 72 hours. The patch is available only by prescription.

If you or a loved one used a Duragesic Patch and suffered side effects, please fill out the form at the right for a free lawsuit case evaluation by Bagolie Friedman Injury Lawyers.